Do analysts rate FATE or NNNN?

Fate Therapeutics presently has a consensus price target of $5.13, indicating a potential upside of 84.02%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, FATE or NNNN?

Anbio Biotechnology has higher revenue and earnings than Fate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fate Therapeutics $6.65M 48.81 -$136.32M -$1.09 N/A Anbio Biotechnology $8.65M 160.33 $6.40M N/A N/A

Fate Therapeutics (FATE) Competitors

$2.80 +0.02 (+0.72%)

Closing price 04:00 PM Eastern

Extended Trading

$2.80 0.00 (-0.18%)

As of 04:24 PM Eastern

Compare

FATE vs. XERS, KALV, INBX, NNNN, and CRVS

Should you buy Fate Therapeutics stock or one of its competitors? MarketBeat compares Fate Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fate Therapeutics include Xeris Biopharma (XERS), KalVista Pharmaceuticals (KALV), Inhibrx Biosciences (INBX), Anbio Biotechnology (NNNN), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry.

How does Fate Therapeutics compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Xeris Biopharma had 3 more articles in the media than Fate Therapeutics. MarketBeat recorded 3 mentions for Xeris Biopharma and 0 mentions for Fate Therapeutics. Xeris Biopharma's average media sentiment score of 0.54 beat Fate Therapeutics' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Xeris Biopharma	Positive
Fate Therapeutics	Neutral

Xeris Biopharma has higher revenue and earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	5.09	$550K	$0.06	143.42
Fate Therapeutics	$6.65M	48.81	-$136.32M	-$1.09	N/A

Xeris Biopharma has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.51, indicating that its stock price is 151% more volatile than the broader market.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Xeris Biopharma has a net margin of 3.81% compared to Fate Therapeutics' net margin of -2,056.79%. Xeris Biopharma's return on equity of 735.00% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

Xeris Biopharma presently has a consensus price target of $10.80, suggesting a potential upside of 25.51%. Fate Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 84.02%. Given Fate Therapeutics' higher possible upside, analysts plainly believe Fate Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Xeris Biopharma beats Fate Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Fate Therapeutics compare to KalVista Pharmaceuticals?

KalVista Pharmaceuticals (NASDAQ:KALV) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

97.5% of Fate Therapeutics shares are held by institutional investors. 4.3% of KalVista Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, KalVista Pharmaceuticals' average media sentiment score of 0.00 equaled Fate Therapeutics'average media sentiment score.

Company	Overall Sentiment
KalVista Pharmaceuticals	Neutral
Fate Therapeutics	Neutral

KalVista Pharmaceuticals has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.51, indicating that its share price is 151% more volatile than the broader market.

KalVista Pharmaceuticals currently has a consensus target price of $33.25, suggesting a potential upside of 23.15%. Fate Therapeutics has a consensus target price of $5.13, suggesting a potential upside of 84.02%. Given Fate Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Fate Therapeutics is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

KalVista Pharmaceuticals has higher earnings, but lower revenue than Fate Therapeutics. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A
Fate Therapeutics	$6.65M	48.81	-$136.32M	-$1.09	N/A

KalVista Pharmaceuticals has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

Summary

Fate Therapeutics beats KalVista Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Fate Therapeutics compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Inhibrx Biosciences has a beta of 3.41, indicating that its stock price is 241% more volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.51, indicating that its stock price is 151% more volatile than the broader market.

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Inhibrx Biosciences has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Fate Therapeutics' return on equity of -58.89% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

In the previous week, Inhibrx Biosciences had 2 more articles in the media than Fate Therapeutics. MarketBeat recorded 2 mentions for Inhibrx Biosciences and 0 mentions for Fate Therapeutics. Inhibrx Biosciences' average media sentiment score of 0.34 beat Fate Therapeutics' score of 0.00 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibrx Biosciences	Neutral
Fate Therapeutics	Neutral

Inhibrx Biosciences presently has a consensus price target of $150.00, suggesting a potential upside of 78.33%. Fate Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 84.02%. Given Fate Therapeutics' higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Fate Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	949.21	-$140.05M	-$8.39	N/A
Fate Therapeutics	$6.65M	48.81	-$136.32M	-$1.09	N/A

Summary

Fate Therapeutics beats Inhibrx Biosciences on 9 of the 17 factors compared between the two stocks.

How does Fate Therapeutics compare to Anbio Biotechnology?

Fate Therapeutics (NASDAQ:FATE) and Anbio Biotechnology (NASDAQ:NNNN) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

Fate Therapeutics has a beta of 2.51, meaning that its share price is 151% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.15, meaning that its share price is 415% more volatile than the broader market.

Anbio Biotechnology has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Anbio Biotechnology's return on equity of 0.00% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%
Anbio Biotechnology	N/A	N/A	N/A

In the previous week, Fate Therapeutics' average media sentiment score of 0.00 equaled Anbio Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Fate Therapeutics	Neutral
Anbio Biotechnology	Neutral

Anbio Biotechnology has higher revenue and earnings than Fate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	48.81	-$136.32M	-$1.09	N/A
Anbio Biotechnology	$8.65M	160.33	$6.40M	N/A	N/A

97.5% of Fate Therapeutics shares are owned by institutional investors. 4.7% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Fate Therapeutics presently has a consensus price target of $5.13, indicating a potential upside of 84.02%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Anbio Biotechnology beats Fate Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Fate Therapeutics compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Corvus Pharmaceuticals has higher earnings, but lower revenue than Fate Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Fate Therapeutics	$6.65M	48.81	-$136.32M	-$1.09	N/A

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Corvus Pharmaceuticals' return on equity of -38.92% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

Corvus Pharmaceuticals presently has a consensus price target of $33.33, suggesting a potential upside of 136.16%. Fate Therapeutics has a consensus price target of $5.13, suggesting a potential upside of 84.02%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Corvus Pharmaceuticals is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Corvus Pharmaceuticals had 5 more articles in the media than Fate Therapeutics. MarketBeat recorded 5 mentions for Corvus Pharmaceuticals and 0 mentions for Fate Therapeutics. Corvus Pharmaceuticals' average media sentiment score of 1.07 beat Fate Therapeutics' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corvus Pharmaceuticals	Positive
Fate Therapeutics	Neutral

Corvus Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.51, suggesting that its stock price is 151% more volatile than the broader market.

Summary

Corvus Pharmaceuticals beats Fate Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Fate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FATE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FATE vs. The Competition

Export

Metric	Fate Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$324.62M	$3.63B	$6.78B	$12.28B
Dividend Yield	N/A	2.17%	2.67%	9.36%
P/E Ratio	-2.56	20.69	27.12	23.98
Price / Sales	48.81	301.68	572.82	112.50
Price / Cash	N/A	60.31	29.05	48.09
Price / Book	1.55	7.92	10.65	6.14
Net Income	-$136.32M	$23.81M	$3.59B	$331.63M
7 Day Performance	-7.78%	-1.68%	-1.61%	-1.68%
1 Month Performance	34.22%	2.17%	1.01%	-1.40%
1 Year Performance	146.46%	42.55%	23.83%	17.10%

Fate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FATE Fate Therapeutics	3.0369 of 5 stars	$2.80 +0.7%	$5.13 +83.0%	+146.0%	$326.37M	$6.65M	N/A	550
XERS Xeris Biopharma	3.2345 of 5 stars	$8.16 -2.2%	$10.80 +32.4%	+72.2%	$1.44B	$291.85M	136.00	290
KALV KalVista Pharmaceuticals	N/A	$27.00 flat	$33.25 +23.1%	N/A	$1.44B	$1.43M	N/A	100
INBX Inhibrx Biosciences	2.2887 of 5 stars	$92.17 -0.9%	$150.00 +62.7%	+257.4%	$1.36B	$1.30M	N/A	166	News Coverage Gap Down
NNNN Anbio Biotechnology	0.3025 of 5 stars	$9.97 +6.2%	N/A	N/A	$1.35B	$8.65M	N/A	27	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FATE) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fate Therapeutics (FATE) Competitors

FATE vs. XERS, KALV, INBX, NNNN, and CRVS

How does Fate Therapeutics compare to Xeris Biopharma?

Summary

How does Fate Therapeutics compare to KalVista Pharmaceuticals?

Summary

How does Fate Therapeutics compare to Inhibrx Biosciences?

Summary

How does Fate Therapeutics compare to Anbio Biotechnology?

Summary

How does Fate Therapeutics compare to Corvus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE vs. The Competition

Fate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fate Therapeutics (FATE) Competitors

FATE vs. XERS, KALV, INBX, NNNN, and CRVS

How does Fate Therapeutics compare to Xeris Biopharma?

Does the media refer more to XERS or FATE?

Which has higher valuation and earnings, XERS or FATE?

Which has more volatility and risk, XERS or FATE?

Do institutionals & insiders have more ownership in XERS or FATE?

Is XERS or FATE more profitable?

Do analysts rate XERS or FATE?

Summary

How does Fate Therapeutics compare to KalVista Pharmaceuticals?

Do insiders & institutionals have more ownership in KALV or FATE?

Does the media refer more to KALV or FATE?

Which has more volatility & risk, KALV or FATE?

Do analysts rate KALV or FATE?

Which has preferable earnings & valuation, KALV or FATE?

Is KALV or FATE more profitable?

Summary

How does Fate Therapeutics compare to Inhibrx Biosciences?

Which has more risk and volatility, INBX or FATE?

Do insiders and institutionals have more ownership in INBX or FATE?

Is INBX or FATE more profitable?

Does the media prefer INBX or FATE?

Do analysts rate INBX or FATE?

Which has stronger earnings and valuation, INBX or FATE?

Summary

How does Fate Therapeutics compare to Anbio Biotechnology?

Which has more risk & volatility, FATE or NNNN?

Is FATE or NNNN more profitable?

Does the media favor FATE or NNNN?

Which has preferable earnings and valuation, FATE or NNNN?

Do insiders & institutionals have more ownership in FATE or NNNN?

Do analysts rate FATE or NNNN?

Summary

How does Fate Therapeutics compare to Corvus Pharmaceuticals?

Which has higher valuation and earnings, CRVS or FATE?

Do institutionals & insiders have more ownership in CRVS or FATE?

Is CRVS or FATE more profitable?

Do analysts prefer CRVS or FATE?

Does the media prefer CRVS or FATE?

Which has more risk & volatility, CRVS or FATE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FATE vs. The Competition

Fate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools